---
document_datetime: 2023-10-31 11:14:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/tevimbra-epar-all-authorised-presentations_en.pdf
document_name: tevimbra-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.2918875
conversion_datetime: 2025-12-18 08:34:40.366989
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical form                   | Route of administration   | Immediate packaging   | Content (concentration)   | Pack size                   |
|------------------|-------------------|------------|---------------------------------------|---------------------------|-----------------------|---------------------------|-----------------------------|
| EU/1/23/1758/001 | Tevimbra          | 100 mg     | Concentrate for solution for infusion | Intravenous use           | vial (glass)          | 10 ml (10 mg/ml)          | 1 vial                      |
| EU/1/23/1758/002 | Tevimbra          | 100 mg     | Concentrate for solution for infusion | Intravenous use           | vial (glass)          | 10 ml (10 mg/ml)          | 2 (2 x 1) vials (multipack) |